All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type ECOG ⩾ 1 ECOG 0 ECOG 1 LDH > ULN LDH ≤ULN PD-L1 < 1% PD-L1 < 5% PD-L1 > 1% PD-L1 > 5% stage M0/M1A/M1B stage M1C
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mML - L1 - all population, nivolumab alone vs. immune chekpoint inhibitors, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 067 (N vs I ; all population), 2015 0.63 [0.48; 0.82]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.54 [1.25; 1.89]
0.99 [0.41 ; 2.37 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 96% 1,261 low not evaluable deaths (OS) (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 0.63 [0.52; 0.76]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.20 [0.97; 1.49]
0.87 [0.46 ; 1.64 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 95% 1,261 low not evaluable PFS (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 0.53 [0.44; 0.64]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.27 [1.03; 1.55]
0.82 [0.35 ; 1.92 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 97% 1,261 low not evaluable progression or deaths (PFS)detailed results CheckMate 067 (N vs I ; all population), 2015 0.57 [0.43; 0.76]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.35 [1.09; 1.67]
0.88 [0.38 ; 2.06 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 96% 1,261 low not evaluable objective responses (ORR)detailed results CheckMate 067 (N vs I ; all population), 2015 3.40 [2.02; 5.72]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.57 [0.42; 0.78]
1.37 [0.24 ; 7.91 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 97% 1,261 low not evaluable objective responses (ORR) (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 3.54 [2.46; 5.10]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.17 [0.12; 0.24]
0.77 [0.04 ; 15.30 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 99% 1,261 low not evaluable TRAE (any grade)detailed results CheckMate 067 (N vs I ; all population), 2015 1.01 [0.64; 1.59]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.28 [0.15; 0.53]
0.54 [0.15 ; 1.90 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 90% 1,250 low not evaluable TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.71 [0.49; 1.03]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.21 [0.15; 0.29]
0.38 [0.11 ; 1.29 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 96% 1,250 low not evaluable TRAE leading to death (grade 5)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.00 [0.02; 50.56]
1.00 [0.06 ; 15.97 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 067 (N vs I ; all population), 2015 0.72 [0.45; 1.13]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.21 [0.14; 0.31]
0.38 [0.11 ; 1.30 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 94% 1,250 low not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.52 [0.31; 0.88]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.20 [0.12; 0.32]
0.32 [0.12 ; 0.82 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 86% 1,250 low not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.25 [0.01; 5.50]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.50 [0.02; 14.93]
0.34 [0.03 ; 3.37 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.33 [0.07; 1.64]
0.64 [0.12 ; 3.54 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 33% 1,250 low not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.50 [0.04; 5.52]
0.79 [0.11 ; 5.64 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.04; 5.49]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.00 [0.06; 16.06]
0.67 [0.11 ; 4.12 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.12 [0.03; 0.39]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.11 [0.03; 0.36]
0.11 [0.05 ; 0.26 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable Cough TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 3.99 [0.18; 88.92]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 4.02 [0.18; 89.49]
4.01 [0.45 ; 35.95 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.12 [0.01; 2.35]
0.22 [0.02 ; 2.08 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.48 [0.21; 1.09]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.29 [0.13; 0.62]
0.37 [0.21 ; 0.64 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable Dry skin TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.00 [0.02; 50.56]
1.00 [0.06 ; 15.97 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable Dyspnoea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.33 [0.03; 3.20]
0.58 [0.09 ; 3.80 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.20; 4.96]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.22 [0.06; 0.79]
0.43 [0.10 ; 1.85 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 51% 1,250 low not evaluable Headache TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.25 [0.01; 5.54]
0.34 [0.03 ; 3.37 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable Hepatitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.10 [0.01; 1.81]
0.22 [0.02 ; 2.32 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.17 [0.01; 3.31]
0.32 [0.03 ; 3.47 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable Hypophysitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.20 [0.02; 1.69]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.20 [0.02; 1.70]
0.20 [0.04 ; 0.90 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.50 [0.02; 14.93]
0.67 [0.05 ; 8.75 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.50 [0.25; 9.01]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.15 [0.04; 0.51]
0.43 [0.05 ; 4.06 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 77% 1,250 low not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.79 [0.21; 2.98]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.14 [0.05; 0.40]
0.31 [0.06 ; 1.75 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 76% 1,250 low not evaluable Increased lipase level TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.17 [0.53; 2.56]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.38 [0.20; 0.73]
0.65 [0.22 ; 1.94 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 78% 1,250 low not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.33 [0.07; 1.64]
0.64 [0.12 ; 3.54 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 33% 1,250 low not evaluable Myalgia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.00 [0.06; 16.06]
1.32 [0.15 ; 11.31 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.25 [0.01; 5.50]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.07 [0.00; 1.24]
0.13 [0.02 ; 1.03 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.33 [0.03; 3.20]
0.51 [0.09 ; 2.98 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable Pruritic rash TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.00 [0.02; 50.56]
1.00 [0.06 ; 15.97 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.16 [0.02; 1.37]
0.32 [0.06 ; 1.76 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 2% 1,250 low not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.25 [0.01; 5.54]
0.34 [0.03 ; 3.37 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.20 [0.02; 1.69]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.10 [0.01; 0.76]
0.14 [0.03 ; 0.60 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable Thyroiditis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.50 [0.02; 14.93]
0.67 [0.05 ; 8.75 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable Vitiligo TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2.00 [0.07; 59.93]
2.00 [0.18 ; 22.08 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.14 [0.02; 1.15]
0.30 [0.05 ; 1.95 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 18% 1,250 low not evaluable Weight decreased TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.00 [0.02; 50.56]
0.67 [0.05 ; 8.74 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2 0% 1,250 low not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-28 12:10 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 68
- treatments: 360,719,721,720